ASCO GI 2024 | Colorectal cancer screening preferences and program effectiveness

Theodore R. Levin, MD, Kaiser Permanente, Oakland, CA, discusses the preference for colonoscopy among American physicians and the effectiveness of stool-based testing, particularly in the context of a well-organized program. At Kaiser Permanente in Northern California, they have implemented a fecal immunochemical test (FIT) based outreach program, resulting in a significant 50% reduction in colorectal cancer mortality and a 25% reduction in colorectal cancer incidence. The program includes colonoscopy for individuals at increased risk, those with positive FIT results, or those choosing colonoscopy for screening. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.